Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
暂无分享,去创建一个
S. Sleijfer | W. Sluiter | A. Danser | A. H. van den Meiracker | J. V. van Esch | A. Danser | M. Kappers | Joep H. M. van Esch
[1] H. Smeets,et al. Patients with Leber hereditary optic neuropathy fail to compensate impaired oxidative phosphorylation. , 2010, Biochimica et biophysica acta.
[2] J. Granger,et al. Role of Endothelin in Mediating Soluble fms-Like Tyrosine Kinase 1–Induced Hypertension in Pregnant Rats , 2010, Hypertension.
[3] S. Sleijfer,et al. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects , 2009, Journal of hypertension.
[4] S. Davidsen,et al. ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats , 2009, Journal of cardiovascular pharmacology.
[5] B. Jessen,et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[6] D. Nochy,et al. VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.
[7] A. Danser,et al. Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptor? , 2008, European journal of pharmacology.
[8] S. Wedge,et al. Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy , 2008, Clinical Cancer Research.
[9] S. Oudard,et al. Home blood-pressure monitoring in patients receiving sunitinib. , 2008, The New England journal of medicine.
[10] David Zurakowski,et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.
[11] H. Izzedine,et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[13] R. A. Etten,et al. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.
[14] W. Dahut,et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] H. V. van Beusekom,et al. Mitochondrial adaptations within chronically ischemic swine myocardium. , 2006, Journal of molecular and cellular cardiology.
[16] H. Gelderblom,et al. VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Flaherty,et al. Mechanisms of hypertension associated with BAY 43-9006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Ping,et al. Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. , 2005, American journal of physiology. Heart and circulatory physiology.
[19] J. Ménard,et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats , 2005, Journal of hypertension.
[20] T. Spector,et al. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.
[21] T. Libermann,et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.
[22] P. Saxena,et al. Restored Capillary Density in Spared Myocardium of Infarcted Rats Improves Ischemic Tolerance , 2002, Journal of cardiovascular pharmacology.
[23] J. Saris,et al. Prorenin Accumulation and Activation in Human Endothelial Cells: Importance of Mannose 6-Phosphate Receptors , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[24] A. J. Man in 't Veld,et al. Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. , 1993, Clinical chemistry.
[25] A. J. Man in 't Veld,et al. Simultaneous determination of catecholamines and dobutamine in human plasma and urine by high-performance liquid chromatography with fluorimetric detection. , 1992, Journal of chromatography.
[26] M. Schalekamp,et al. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. , 1986, The Journal of clinical endocrinology and metabolism.
[27] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[28] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] P. Gathiram,et al. Immunolocalisation and endothelin-1 values In pre-eclampsia: an immunocytochemical study. , 2001, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.